China-based Dialaibo (Zhangjiagang) Biotechnology Co., Ltd has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A finance round. The round was led by Grand Yangtze Capital, with participation from Shulan Junjie Capital, Zhangjiagang Jinmao Venture Capital, Zhangjiagang Talent No.1 Fund, and Zhangjiagang Bonded Area Wisdom Venture Capital. The funds raised will be allocated towards new product research and development (R&D), improving manufacturing capacity, and accelerating clinical studies.
Company Overview and Focus on Diagnostics
Founded in 2016, Dialaibo is dedicated to the research and development of laboratory testing products that target autoimmune diseases and nervous system diseases. With R&D centers located in Shanghai and Zhangjiagang, Jiangsu province, the company has established a strong presence in the diagnostics market. Dialaibo boasts over 40 chemiluminescence product marketing approvals and has received multiple approvals for single-person, fast, and quantitative autoimmune disease testing products.
Investment Impact and Future Prospects
The investment from the Series A finance round is expected to significantly bolster Dialaibo’s capabilities in new product development, enhance its manufacturing processes, and expedite clinical studies. This financial boost positions Dialaibo to expand its offerings and improve its competitive edge in the diagnostics industry, particularly in the critical areas of autoimmune and nervous system disease diagnostics.-Fineline Info & Tech
